Approximately half of the patients with intermediate grade non-Hodgkin's lymphoma can be cured with combination In an effort to decrease the relapse rate following autochemotherapy. However, the survival of those patients who logous bone marrow transplantation for non-Hodgkin's are refractory or relapse after conventional chemotherapy lymphoma, patients were given cyclosporine and interis short when treated with standard salvage chemotherapy feron following autologous marrow transplantation.
These antitumor effects are tors for relapse post-transplant. Disease-free survival of mediated by cytotoxic T-lymphocytes that target class II all patients is 77% (95% confidence interval, 67-93%).
HLA antigens. The antitumor effects appear to be augThe results of this pilot study suggest that the adminismented by interferon presumably due to increased tration of cyclosporine and interferon may decrease the expression of class II HLA antigens on the tumor. Human relapse rate of relapsed/refractory non-Hodgkin's lymstudies have confirmed that autologous GVHD is produced phoma following autologous bone marrow transplanin a dose-dependent manner to the amount of cyclosporine tation that is administered post-transplant. 9 Since the majority of Keywords: graft-versus-host disease; non-Hodgkin's lymphoma; marrow transplantation intermediate grade non-Hodgkin's lymphomas (NHL) express class II HLA antigens, 10 a phase II study of autologous bone marrow transplantation followed by administration of cyclosporine and interferon was performed in patients who were refractory or who relapsed following initial chemotherapy.
Patients and methods
sporine was then continued at 1.2 mg/kg q 8 h until day 28. Cyclosporine levels were monitored three times per week. The dose was adjusted to maintain a trough level of 150-Eligibility criteria 350 ng/ml (HPLC). Those patients who could take mediAll patients gave written consent using forms approved by cation orally were given oral cyclosporine at three to four the Institutional Research Board of Cooper Hospital. The times the intravenous dose and levels were followed. Oral study was opened in November 1990. Consecutive patients cyclosporine was not attempted prior to day 14 post-trans-Ͻ70 years of age with documented intermediate grade nonplant. This schedule of cyclosporine administration is curHodgkin's lymphoma (Working Formulation D-G) that rently used for allogeneic marrow transplantation at Cooper was either in relapse or refractory to chemotherapy were Hospital and was chosen for its known toxicity profile. eligible. No eligible patients were excluded from the study.
Alpha-interferon was begun when the platelet count was Refractory disease was defined by a less than 50% response Ͼ50 000/l. The initial dose was 500 000 U s.c. every to the last chemotherapy regimen. Patients who had CNS other day. Attempts at starting higher doses led to delayed lymphoma or were HIV positive were excluded. Adequate engraftment (unpublished data). After 1-2 weeks, the dose organ function was required with total bilirubin and creatinwas gradually increased to 1 500 000 U s.c. daily. This dose ine of less than 2 mg/dl. Left ventricular ejection fraction was maintained for 2 years following transplantation. and pulmonary diffusing capacity were required to be у50%. Normal WBC and platelet counts were required Supportive care prior to harvesting. Patients who required chronic steroids were excluded from the study.
Patients were hospitalized in private rooms with HEPA air filtration. All patients received either fluconazole (400 mg daily) or amphotericin (20 mg daily) beginning on day 1 Bone marrow collection post-BMT and continuing until neutropenia resolved. GBone marrow was harvested from the posterior iliac crests CSF (300 g s.c. twice a day) was started on day 1 and of the patients under general anesthesia; 2-3 × 10 8 WBC/kg continued until WBCϾ10 000/l. All blood products were were collected. Buffy coat preparations were prepared on irradiated with 2500 cGy. Platelets were transfused to maina COBE Spectra (Lakewood, CO, USA). Dimethyl sulfoxtain a count of Ͼ18 000/l. Total bilirubin was followed ide was added to a final concentration of 10% and the cell daily. When the total bilirubin rose to between 3-5 mg/dl, suspension was placed in a −70°C freezer overnight (nontissue plasminogen activator (TPA-activase; Gentech, San controlled rate freezing). Cells were then transferred to the Francisco, CA, USA) 20 mg in 100 ml NSS was infused liquid phase of a liquid nitrogen freezer. Aliquots of the over 100 min daily for 2 days or until the total bilirubin frozen marrow were tested for sterility. CFU-GM growth stopped rising. Heparin 150 U/kg/day was given as a conwas documented with a commercial (Gibco, Gaithersburg, tinuous infusion until the bilirubin normalized. Total par-MD, USA) methylcellulose assay. Thirty-six hours after the enteral nutrition was given to those patients who did not completion of chemotherapy, each 100 ml bag was thawed have oral intake for at least 48 h. in a warm water bath at the bedside and infused immediately. Vancomycin (1 gram i.v.) was given following Patient characteristics marrow infusion.
Patient characteristics are detailed in Table 1 . Patients had either primary refractory disease or disease that had Preparative chemotherapy relapsed after initial complete remission.The median age at Following insertion of Hickman catheters, i.v. hydration of time of marrow transplantation was 45 years. All patients at least 150 ml/h was started. Chemotherapy consisted of with relapsed disease were treated with a salvage regimen cyclophosphamide 850 mg/m 2 every 12 h for eight doses, but were transplanted regardless of their response to the etoposide 200 mg/m 2 every 12 h for eight doses, and carsalvage chemotherapy. Although 16 patients (40%) were mustine 100 mg/m 2 daily for four doses. Dexamethasone treated with 2500-4500 cGy involved field radiation ther-(10 mg i.v. daily) and ondansetron were used as anti-emetapy prior to transplant, responsive disease was defined as a ics. Three-way Foley catheters were inserted in all patients 50% or greater response to the last chemotherapy regimen. prior to the start of chemotherapy. Normal saline was infused as continuous bladder irrigation at a rate of 250 ml/h and continued for 24 h after the end of cyclophosResults phamide. Chemotherapy doses were based on either the ideal body weight or (in cases of obesity): ideal Engraftment weight + 10% (actual − ideal weights). Patients with prior chest irradiation received 80 mg/m 2 BCNU for four doses. All harvests were documented to contain greater than Patients over age 55 received a 10% dose reduction.
5 × 10 3 CFU-GM/kg. Engraftment was prompt in most patients. The median number of days with WBC Ͻ500/l was 12 (range, 7-28). The median number of days with Administration of cyclosporine and interferon platelets Ͻ25 000/l was 22 (range, 18-70). Only one patient failed to engraft. This patient had evidence of bone Cyclosporine 16 mg/kg (actual body weight) was given as a 24-h continuous infusion on day −1. Intravenous cyclomarrow involvement by lymphoma (Ͻ10% by 223 This responsed to the combination of increased platelet III 18 transfusions and reinsertion of the Foley catheter with blad- IV 14 der irrigation. Patients were discharged from the hospital pericarditis has responded to indomethacin.
Bone marrow involvement By history but not at harvesting 3 At harvesting (Ͻ10% by morphology) 2
Assessment of erythroderma
A summary of the erythroderma is provided in Table 2 . Erythema beginning on the palms and soles was noted in 21 patients (53%). Biopsies of the skin performed 3-5 days morphology) at time of harvesting. The patient expired of after the appearance of erythema revealed epidermal basal Staphylococcal pneumonia 30 days after transplant without cell vacuolization consistent with grade I GVHD. All any evidence of engraftment.
biopsies were read in an unblinded fashion by a pathologist and one of the investigators. Several additional patients Regimen-related toxicity developed erythema of the trunk. Skin biopsy of these patients was either consistent with drug reaction or nonFour patients (10%) died of regimen-related toxicities diagnosis. The erythroderma began a median of 20 days (RRT). One patient died of veno-occlusive disease of the post-transplant (range, 14-42). However, initiation of interliver, one patient developed pulmonary aspergillosis, one feron therapy started a median of 24 days post-transplant patient with prior chest irradiation developed interstitial (range, 18-50). No patients required therapy for the reacpneumonitis, and one patient expired from staphylococcal tion and rashes persisted a median of 10 days (range, 6-pneumonia. Mucositis was significant. Thirty-six patients 28). At maximum expression, the erythroderma covered a (90%) developed grade II-IV mucositis and 29 patients mean of 25% of the body surface area (range, 5-36%). No (73%) required parenteral narcotics for the mucositis.
patients developed evidence of visceral GVHD. However, Fevers with or without documented organisms were univertwo patients developed sterile conjunctivitis at the point of sal. Among the first 10 patients treated with fluconazole, their maximum skin rash (day 35 post-BMT). Both of these there were three resistant Candida species isolated. Therepatients responded to a 5-day course of dexamethasone after, all patients were treated with prophylactic amphoeye drops. tericin B. Hyperbilirubinemia was common. This was usually treated with TPA/heparin before the development of weight gain and right upper quadrant pain that is associated Response with veno-occlusive liver disease. Twenty-two patients
Patients underwent restaging of their disease between days (55%) developed a total bilirubin of Ͼ3 mg/dl within 3 30 and 60 following transplantation. Thirty patients had no weeks of transplant. These patients were treated with TPA regardless of associated findings or heme-positive stools. (2), epistaxis (2), mucositis (2), and melena/hematemesis (2). TPA/heparin administration was interrupted only for evidence of disease following marrow transplantation. Ten Discussion patients (25%) had residual masses or adenopathy. Three of these developed relapsed disease within 6 months of In recent years, multiple trials have defined the maximum doses of combination chemotherapy or the combination of transplantation. The remaining seven patients have had no change in their residual adenopathy for 12-60 months. chemotherapy and total body irradiation that can be safely used during bone marrow transplantation. Further dose They are therefore considered disease-free. 12 Out of the five patients who had relapsed disease following transplanescalations lead to significant mortality from extramedullary toxicity. Despite the use of these high-dose regimens, tation, three of these were categorized as having disease that was refractory to their last chemotherapy regimen.
the relapse rate for non-Hodgkin's lymphomas following autologous bone marrow transplantation remains in excess These three patients had disease that measured between 6-15 cm at time of transplant and all relapsed at sites of their of 50%. Immunotherapy following autologous BMT offers one avenue of hope for decreasing the relapse rate in these original disease. One patient in second partial remission developed recurrent lymphoma in a new site (liver). One patients. Several immunomodulators such as IL-2 14 or interferon 15 appear to decrease post-BMT relapse rates in phase additional patient who was in (third) complete remission at time of transplant developed relapsed lymphoma during the II trials but add considerable toxicities to the immediate post-transplant period. 16, 17 Specific monoclonal antibodies first year after transplant at a new site (lung). Of the two patients who had minimal marrow involvement at time of have been shown to eradicate minimal residual disease post-transplant 18 but long-term survival data is lacking. harvesting, one patient died of transplant-related toxicities and one relapsed shortly after transplant. None of the five
The infectious and extramedullary toxicities seen in this trial are comparable to a phase I trial of identical chemopatients who relapsed following transplant developed erythema consistent with autologous GVHD at any time. Howtherapy given without cyclosporine. 19 The use of tissue plasminogen activator (TPA) and heparin for mild hyperbiever, 11 out of the 31 patients who did not relapse also showed no signs of erythroderma.
lirubinemia is controversial since mild elevations of bilirubin with or without other signs of veno-occlusive liver disOverall survival did not differ significantly from diseasefree survival since all five patients with relapsing lymease often reverse spontaneously. 11 Following discharge, the chronic morbidities of this study did not differ from phoma post-transplant had a very fulminant course and succumbed to their lymphoma within 6 weeks. Disease-free previous autologous transplant studies 20 and there was no evidence of chronic GVHD. survival is calculated in Figure 1 using Kaplan-Meier analysis. 13 No patients were lost to follow-up. At a median The administration of cyclosporine following syngeneic or autologous BMT produces an autoaggressive syndrome follow-up of 24 months, the disease-free survival of all patients is 77% (95% confidence interval, 64-90%). Risk that is similar to graft-versus-host disease by histology. This syndrome is the result of at least two separate effects factors for disease relapse following marrow transplantation were analyzed. Variables that were included in the analysis of cyclosporine. 21 First, administration of cyclosporine allows the appearance of autoreactive T-lymphocytes that were: age, response to last chemotherapy regimen, remission status at time of transplant, and presence of are toxic for cells bearing class II HLA antigens. Second, cyclosporine prevents the development of an autoregulatory erythroderma. Univariant analysis (Cox-Mantel) demonstrated associations between the absence of erythroderma mechanism that suppresses the autoreactive T-lymphocytes.
This regulatory mechanism appears to be a subset of CD4 + (P = 0.012) or the presence of Ͼ5 cm of disease at time of transplant (P = 0.02) with increased relapse rates following lymphocytes with an alpha/beta T cell receptor that is capable of interacting with class II HLA determinants on the transplant. However, multivariant analysis (Cox proportional hazards) could not identify any variable as an autoreactive lymphocytes. Since autologous GVHD targets class II HLA antigens, interferons which are known reguindependent predictor of relapse.
lators of HLA antigen expression have been shown to augment autologous GVHD. 22, 23 In the present study, alphainterferon was started after platelet engraftment (which was usually after the clinical appearance of erythroderma) since our own pilot data 24 as well as other studies 23 demonstrated significant side-effects from the early administration of interferon following BMT. This delay in interferon administration may have a negative effect on the antitumor effects of autologous GVHD. Future trials could investigate the use of lower interferon doses along with earlier administration. The incidence and timing of erythema in this series is similar to other trials. 9, 22 Although the histology of the erythroderma was consistent with grade I GVHD, this study was unable to definitively prove the presence of GVHD by biopsy. The basal cell vacuolization that was noted in these biopsies is non-specific and is commonly noted post-trans- GVHD have noted higher grades of cutaneous GVHD. This may be due to the fact that interferon was not initiated until relapsed following transplant in this trial had bulky refractory disease at the time of transplant. The presence of lymafter platelet engraftment. This occurred following skin biopsies in all cases. Those patients who did not have eviphoma may interfere with the development of autologous GVHD and influence the multivariant analysis of predictors dence of erythema involving the palms and soles were not biopsied. Although the histologic pattern of mild GVHD of relapse. Fourth, immunophenotyping of the lymphomas has not been analyzed as a predictor of relapse. Those lymcan be seen in these patients, the significance of this findings is debated. 25 Visceral GVHD was not a feature of this phomas that express target antigens (such as class II HLA or B7 antigens) may be more susceptible to immunotherinvestigation. This is identical to other trials that have employed cyclosporine post-autologous transplant.
apy. This could ultimately determine which patients would benefit from post-transplant immunomodulation. Recently, there have been reports of autologous GVHD involving the liver or GI tract. 26, 27 However, these reports Last, it is possible that the increased survival noted in this study is due only to the administration of interferon have universally used IL-2 to induce autologous GVHD and may act via a different mechanism. Of interest is the post-transplant and is not related to cyclosporine administration. A large randomized, prospective trial is currently fact that two of the patients developed symptomatic, bilateral conjunctivitis that was culture-negative and responded defining the role of interferon (as a single agent) in these patients (Schering-Plough Research Institute, personal to a short course of steroid eye drops. Both patients had marked erythema over 35% of their body surface area at communication).
The results of this trial are encouraging and a larger prothe time of conjunctivitis. Conjunctivitis has been noted both as a complication of routine autologous bone marrow spective, randomized trial is indicated to determine both the true incidence of autologous GVHD and to define the transplants 28 and as a complication of allogeneic GVHD. 29 Therefore, the relation between the conjunctivitis and erypopulation that would be best served by this type of immunotherapy. thema is uncertain.
The most striking feature of this study is the low relapse rate. In both this study and previously published investiReferences gations, the majority of relapses occurred within 1-2 years following transplantation. Therefore, longer follow-up will
